针对 SARS-CoV-2 感染的候选化学药物和中药的抗病毒机制。
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
机构信息
Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Military Veterinary Institute, Academy of Military Medical Sciences, Changchun, 130122, China.
Key Lab for Zoonoses Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, China.
出版信息
Virus Res. 2020 Sep;286:198073. doi: 10.1016/j.virusres.2020.198073. Epub 2020 Jun 24.
Abstract
The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic. Up to now, numerous medicines have been applied or approved for the prevention and control of the virus infection. However, the efficiency of each medicine or combination is completely different or still unknown. In this review, we discuss the types, characteristics, antiviral mechanisms, and shortcomings of recommended candidate medicines for SARS-CoV-2 infection, as well as perspectives of the drugs for the disease treatment, which may provide a theoretical basis for drug screening and application.
摘要
由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）已迅速成为全球性大流行。迄今为止，已有多种药物被应用或批准用于预防和控制病毒感染。然而，每种药物或联合用药的疗效完全不同，甚至仍不明确。在这篇综述中，我们讨论了推荐用于 SARS-CoV-2 感染的候选药物的类型、特点、抗病毒机制和缺点，以及这些药物治疗疾病的前景，这可能为药物筛选和应用提供理论依据。
相似文献
1
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.针对 SARS-CoV-2 感染的候选化学药物和中药的抗病毒机制。
Virus Res. 2020 Sep;286:198073. doi: 10.1016/j.virusres.2020.198073. Epub 2020 Jun 24.
2
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.中国治疗新型冠状病毒肺炎（COVID-19）的潜在药物。
Virus Res. 2020 Sep;286:198057. doi: 10.1016/j.virusres.2020.198057. Epub 2020 Jun 9.
3
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
4
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.新型冠状病毒治疗药物的安全性、临床应用和抗病毒研究概述。
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
5
Treatment options for COVID-19: The reality and challenges.治疗 COVID-19 的选择：现实与挑战。
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
6
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
7
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.当前用于管理新型冠状病毒病 2019（COVID-19）的药理学方法及其利用的原理：综述。
Rev Med Virol. 2020 Sep;30(5):e2136. doi: 10.1002/rmv.2136. Epub 2020 Jul 9.
8
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
9
Potential strategies for combating COVID-19.应对 COVID-19 的潜在策略。
Arch Virol. 2020 Nov;165(11):2419-2438. doi: 10.1007/s00705-020-04768-3. Epub 2020 Aug 10.
10
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.用于 SARS-CoV-2 治疗的潜在抗病毒药物：临床前发现和正在进行的临床研究。
In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949.
引用本文的文献
1
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.冠状病毒感染的叙述性概述：临床体征和症状、病毒进入和复制、治疗方式和管理。
Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058.
2
Contributory role of SARS-CoV-2 genomic variations and life expectancy in COVID-19 transmission and low fatality rate in Africa.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）基因组变异和预期寿命在非洲新冠病毒疾病（COVID-19）传播及低病死率中的作用
Egypt J Med Hum Genet. 2020;21(1):72. doi: 10.1186/s43042-020-00116-x. Epub 2020 Dec 9.
3
Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.吲哚类化合物作为 SARS-CoV-2 的潜在药物候选物。
Molecules. 2023 Sep 13;28(18):6603. doi: 10.3390/molecules28186603.
4
Herbal supplements as treatment options for COVID-19: A call for clinical development of herbal supplements for emerging and re-emerging viral threats in Sub-Saharan Africa.草药补充剂作为治疗新冠肺炎的选择：呼吁对撒哈拉以南非洲新出现和再次出现的病毒威胁进行草药补充剂的临床开发。
Sci Afr. 2023 Jul;20:e01627. doi: 10.1016/j.sciaf.2023.e01627. Epub 2023 Mar 5.
5
Flavonoids as Potential Antiviral Agents for Porcine Viruses.黄酮类化合物作为猪病毒的潜在抗病毒剂
Pharmaceutics. 2022 Aug 26;14(9):1793. doi: 10.3390/pharmaceutics14091793.
6
Discovery of TCMs and derivatives against the main protease of SARS-CoV-2 via high throughput screening, ADMET analysis, and inhibition assay in vitro.通过高通量筛选、ADMET分析和体外抑制试验发现抗新型冠状病毒主要蛋白酶的中药及其衍生物。
J Mol Struct. 2022 Nov 15;1268:133709. doi: 10.1016/j.molstruc.2022.133709. Epub 2022 Jul 12.
7
The Impact of COVID-19 Pandemic on Seafood Safety and Human Health.新冠疫情对海鲜安全及人类健康的影响
Front Microbiol. 2022 Jun 22;13:875164. doi: 10.3389/fmicb.2022.875164. eCollection 2022.
8
Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein.叶酸：一种潜在的抗 SARS-CoV-2 核衣壳蛋白抑制剂。
Pharm Biol. 2022 Dec;60(1):862-878. doi: 10.1080/13880209.2022.2063341.
9
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.索磷布韦联合利巴韦林治疗埃及 COVID-19 患者的疗效与标准治疗相比：一项随机对照试验。
J Med Life. 2022 Mar;15(3):350-358. doi: 10.25122/jml-2021-0175.
10
Postcovid-19 Asthenic Syndrome.新冠后乏力综合征
Neurosci Behav Physiol. 2022;52(2):191-195. doi: 10.1007/s11055-022-01222-6. Epub 2022 Mar 18.
本文引用的文献
1
Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.连花清瘟胶囊治疗新型冠状病毒肺炎有效性和安全性的多中心前瞻性随机对照临床试验
Phytomedicine. 2021 May;85:153242. doi: 10.1016/j.phymed.2020.153242. Epub 2020 May 16.
2
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.CD147-刺突蛋白是 SARS-CoV-2 感染宿主细胞的新途径。
Signal Transduct Target Ther. 2020 Dec 4;5(1):283. doi: 10.1038/s41392-020-00426-x.
3
Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.氯喹和羟氯喹安全性概况评估：一项系统评价与荟萃分析
Front Pharmacol. 2020 Oct 14;11:562777. doi: 10.3389/fphar.2020.562777. eCollection 2020.
4
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.评估单独使用羟氯喹或联合使用阿奇霉素在重症监护病房治疗的 2019 年冠状病毒病（COVID-19）感染患者的 QT 间期。
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.
5
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
6
AGTR2, One Possible Novel Key Gene for the Entry of SARS-CoV-2 Into Human Cells.血管紧张素 II 受体 2（AGTR2），新冠病毒进入人体细胞的一个可能的新关键基因。
IEEE/ACM Trans Comput Biol Bioinform. 2021 Jul-Aug;18(4):1230-1233. doi: 10.1109/TCBB.2020.3009099. Epub 2021 Aug 6.
7
Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.重新利用药物对抗 SARS-CoV-2 的主蛋白酶：基于机制的见解，得到了现有实验室和临床数据的支持。
Mol Omics. 2020 Oct 1;16(5):474-491. doi: 10.1039/d0mo00057d. Epub 2020 Jul 22.
8
Dexamethasone for COVID-19? Not so fast.地塞米松治疗 COVID-19？先别急。
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
9
Coronavirus breakthrough: dexamethasone is first drug shown to save lives.冠状病毒研究突破：地塞米松是首个被证明能挽救生命的药物。
Nature. 2020 Jun;582(7813):469. doi: 10.1038/d41586-020-01824-5.
10
[Nationwide survey on clinical treatment of coronavirus disease 2019 in 9 provinces and municipalities].[九省市新型冠状病毒肺炎临床治疗情况的全国性调查]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Apr;32(4):397-400. doi: 10.3760/cma.j.cn121430-20200313-00338.
Zotero 插件